# PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

> **NCT07043907** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shenzhen Celconta Life Science Co., Ltd.** · enrollment: 115 (estimated)

## Conditions studied

- Stage IIIA Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT07043907
- **Lead sponsor:** Shenzhen Celconta Life Science Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2028-07-08
- **Final completion:** 2029-06-18
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07043907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07043907, "PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07043907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*